SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following a positive analyst upgrade that highlights the company's progress in regulatory pathways and validates the therapeutic potential of its lead candidate, Sonelokimab. Investors are actively discussing the stock's significant long-term growth prospects, the potential for a strategic buyout, and the upcoming clinical data readouts that are expected to solidify the drug's position as a best-in-class treatment.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is trending following a series of significant Department of Defense and defense-contractor awards, which have sparked intense community debate over the company's long-term production scalability and balance sheet health. While bulls point to these mission-critical manufacturing contracts as validation of the company's technology, short-sellers and skeptical investors remain focused on ongoing cash burn concerns and the potential for future equity dilution.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is facing intense volatility as shareholders grapple with the end of a major lock-up period and skepticism following a disappointing earnings report that revealed a lack of near-term tenant revenue. The community is sharply divided, with some investors aggressively calling for leadership changes and reporting the firm to the SEC, while others view the current price drop as a strategic buying opportunity in anticipation of future data center power demand.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors gear up for the upcoming fiscal year-end and 10-K filing, with the community highly focused on QNX revenue growth, backlog expansion, and the impact of the new Alloy Kore platform. Shareholders are actively debating management's guidance and the potential for a long-awaited breakout as they look for concrete signs of sustainable double-digit growth.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors weigh strong AI licensing potential and institutional backing against lingering concerns over platform monetization and data integrity. While community members debate whether the stock is a long-term growth play or currently oversold, high-profile litigation updates regarding content scraping continue to fuel active discussion about the company's valuation.

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

United Therapeutics is trending following positive trial data from its TETON-1 study, which demonstrated that nebulized Tyvaso significantly preserves lung function in patients with idiopathic pulmonary fibrosis. The community is actively discussing the potential for a major label expansion that could triple the addressable market for the therapy, leading to multiple analyst price target increases as the company prepares for an FDA submission.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE is trending as the community leans into its roots as a foundational internet meme, bolstered by the restoration of its original RageBuilder and Ragemaker tools. Enthusiasts are actively rallying around the project as a long-term culture play, emphasizing organic growth and community-driven content production as they target long-term valuation milestones.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is seeing heightened trading activity as the company's recent operational updates and offtake agreements drive significant investor interest, leading to strong buying momentum in the stock. The community is actively debating the stock's potential for a breakout, with many discussing the impact of lithium supply-demand dynamics and monitoring insider buying as a key indicator of confidence in future growth.

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific Corp.

Boston Scientific is currently trending as the community debates its future following a major strategic shift to discontinue its Aortic Valve Systems, which has sparked discussions about potential impact on long-term margins and resource allocation. Meanwhile, investors are closely monitoring the stock's resilient momentum and recent bullish analyst outlooks that emphasize strong growth in the company's cardiovascular and electrophysiology segments.

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is facing significant downward pressure following the release of phase 3 clinical trial data for its thyroid eye disease drug, elegrobart, which failed to demonstrate the level of efficacy compared to IV-based treatments that investors had hoped for. While management emphasizes the drug's safety profile and ongoing clinical progress, market participants are actively debating the competitive threat from established standards of care and potential future rivals, leading to increased volatility and a sharp decline in share price.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The company said its NOOR Collagen supplement is projected to generate over $12 million in annualized revenue.</li><li>Cosmos said the impact on operations due to the Middle East conflict is negligible.</li><li>The firm is in the process of acquiring a Greece-based pharmacy distribution network.</li></ul>Cosmos Health Inc (COSM) drew retail attention on Thursday after the company said it is exploring potential capital-raising options, including monetizing non-core assets, to address what it described as a “valuation disconnect”.The company said its shares are currently trading well below book value, adding that its market capitalization does not fully reflect the strength of its operations or the value of its diversified asset base. Management said it may use proceeds to support strategic investments, acquisitions, and possible share buybacks.<a href="https://stocktwits.com/symbol/COSM">COSM shares</a> were up around 3% at $0.3. The company has a price-to-book ratio of 0.67 compared to the industry average of 4.48, according to Investing.com.<h2 class="st-heading-2">Cosmos’ Sky Premium Life Brand To Generate 75% Gross Margin</h2>Cosmos Health expects gross margins of around 75% and strong cash flow from its U.S. operations for the Sky Premium Life brand. Sky Premium sells nutraceuticals, vitamins, and food supplements. The company said its NOOR Collagen supplement alone is projected to generate over $12 million in annualized revenue.The company stated it is actively advancing its acquisition strategy, highlighted by a recent letter of intent to acquire a Greece-based pharmacy distribution network generating approximately $11.5 million in annual revenue. The move supports the company’s broader plan to scale operations and achieve its 2027 revenue target of $155.8 million.Cosmos Health also said that the recent global geopolitical conflict has had a negligible impact on its operations.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, but chatter was mixed. One user expects a 90% to 95% increase in the stock’s price from its record lows of $0.28.<stembedurl>https://stocktwits.com/Letsgetpd/message/648003039</stembedurl>Another user said the stock has plenty of room to continue falling.<stembedurl>https://stocktwits.com/Stopcryin/message/647973933</stembedurl>The stock has been under selling pressure so far this year, with shares down around 35%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/humacyte-secures-saudi-order-why-did-huma-stock-crash-to-record-low/cZ3ao9nRIhh">Humacyte Secures $1.5M Saudi Order – Why Did HUMA Stock Crash To Record Low Today?</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart on black background. | Image source: Getty Images

This Nano Cap Pharmaceutical Company Flags ‘Valuation Disconnect’ –  But Retail Sees Upto 95% Upside From Record Lows

Cosmos Health expects gross margins of around 75% and strong cash flow from the U.S. operations of its Sky Premium Life brand

COSM Stock In Spotlight As Company Explores Raising Capital To Address ‘Valuation Disconnect’  

Equity

Grigorios Siokas Acquires 388,532 Shares of Cosmos Health (NASDAQ:COSM) Stock

Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas acquired 388,532 shares of the stock in a transaction dated Thursday, February 12th. The shares were bought at an average cost...

Cosmos Health (NASDAQ:COSM) CEO Buys $119,417.42 in Stock

Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas purchased 291,262 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was acquired at an...

Cosmos Health (NASDAQ:COSM) CEO Purchases $176,660.50 in Stock

Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas acquired 353,321 shares of Cosmos Health stock in a transaction on Tuesday, January 20th. The shares were bought at an average...

Grigorios Siokas Buys 493,495 Shares of Cosmos Health (NASDAQ:COSM) Stock

Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas purchased 493,495 shares of the firm's stock in a transaction on Wednesday, January 14th. The shares were acquired at an...

Cosmos Health (NASDAQ:COSM) CEO Acquires $43,273.86 in Stock

Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas bought 88,314 shares of the stock in a transaction dated Friday, December 19th. The shares were purchased at an average cost of...

Cosmos Health (NASDAQ:COSM) CEO Grigorios Siokas Acquires 168,472 Shares

Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas acquired 168,472 shares of the business's stock in a transaction that occurred on Monday, December 15th. The shares were bought...

Grigorios Siokas Purchases 76,360 Shares of Cosmos Health (NASDAQ:COSM) Stock

Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas acquired 76,360 shares of the business's stock in a transaction dated Friday, November 28th. The stock was acquired at an...

Insider Buying: Cosmos Health (NASDAQ:COSM) CEO Buys $35,111.16 in Stock

Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas bought 55,732 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were bought at an...

Grigorios Siokas Buys 51,315 Shares of Cosmos Health (NASDAQ:COSM) Stock

Cosmos Health Inc. (NASDAQ:COSM - Get Free Report) CEO Grigorios Siokas purchased 51,315 shares of Cosmos Health stock in a transaction on Thursday, November 20th. The stock was bought at an average...

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Thessaloniki, Greece.

Cosmos Health Inc

Fred Wilson - Union Square Ventures

Abigail Johnson - Fidelity

Jim Cramer - Media Personality

Josh Brown - Ritholtz Wealth Management

A lifetime achievement for industry titans. This honor is reserved for an individual whose groundbreaking contributions have shaped the investing landscape and how we engage with the markets.

COSM
Cosmos Health Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest COSM News

COSMCosmos Health Inc.